SHC Sotera Health

Sotera Health Announces Second-Quarter 2022 Earnings Release Date

Sotera Health Announces Second-Quarter 2022 Earnings Release Date

Names Michael F. Biehl as Interim Chief Financial Officer

CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second quarter ended June 30, 2022, before the Nasdaq market open on Thursday, August 4, 2022. Following the release, management will hold a conference call at 9:00a.m. Eastern Time to discuss the Company’s operating highlights and financial results.

Participants may access the conference call live via webcast on the ‘Presentations & Events' page of Sotera Health’s website at . To participate via telephone, registration is required. The Company advises attendees to register in advance at this  to avoid delays in joining the call. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.

Chief Financial Officer Update

Sotera Health Company has engaged a national executive search firm to lead the search for a new Chief Financial Officer (CFO). While that search is ongoing, Sotera Health is pleased to announce the appointment of Michael F. Biehl as its Interim CFO, effective July 20, 2022. Mr. Biehl replaces Scott Leffler, who has departed the Company. He brings nearly 20 years of public company CFO experience and 30 years of executive leadership to Sotera Health. Mr. Biehl previously held public company CFO positions at Fairmount Santrol and Chart Industries.

Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at . For developments related to Ethylene Oxide, updates can be found at .

About Sotera Health

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

Contacts 
Joseph VitaleJason Peterson
VP Investor Relations, Sotera HealthTreasurer, Sotera Health
  
Kristin Gibbs 
Chief Marketing Officer, Sotera Health 
 

Source: Sotera Health Company



EN
20/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sotera Health

 PRESS RELEASE

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Announces Secondary Offering of Common Stock CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not ...

 PRESS RELEASE

Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Resul...

Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results Q3 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis(1), compared to Q3 2024Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024Q3 2025 Adjusted EBITDA(1) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024Q3 2025 Adjusted EPS(1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted EPS of $0.17 in Q3 2024Raising 2025 Adjusted EBITDA growth r...

 PRESS RELEASE

Sotera Health Announces Third-Quarter 2025 Earnings Release Date

Sotera Health Announces Third-Quarter 2025 Earnings Release Date CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the third-quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s financial results and oper...

 PRESS RELEASE

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Announces Secondary Offering of Common Stock CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not...

 PRESS RELEASE

Sotera Health Reports Strong Second-Quarter and First-Half 2025 Result...

Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues ou...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch